These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32677247)

  • 1. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
    Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
    Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
    Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
    J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
    Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
    Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature.
    Salvatori S; Marafini I; Monteleone G
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1046-e1050. PubMed ID: 33905217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
    Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
    Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review.
    Neves JM; Cunha N; Lencastre A; Cabete J
    Int J Dermatol; 2019 Nov; 58(11):e226-e228. PubMed ID: 31290151
    [No Abstract]   [Full Text] [Related]  

  • 9. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
    Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
    Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New onset of articular inflammatory manifestations in patients with hidradenitis suppurativa under treatment with infliximab.
    Acquacalda E; Roux CH; Albert C; Breuil V; Passeron T; Euller-Ziegler L
    Joint Bone Spine; 2015 Oct; 82(5):362-4. PubMed ID: 25776450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P; Akoglu G; Dalkıran CD; Caliskan E
    Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to 'Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab"'.
    López Sanz P; Guzmán Pérez M; Guerrero Ramírez C; Manso Córdoba S; Alfaro Martínez ME; Azaña Defez JM
    Clin Exp Dermatol; 2023 Jul; 48(8):940-941. PubMed ID: 37098182
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
    Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
    Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
    Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab-induced paradoxical hidradenitis suppurativa.
    Navarro-Triviño FJ; Sanchez-Parera R; Ruiz-Villaverde R
    Dermatol Ther; 2020 Jan; 33(1):e13150. PubMed ID: 31670893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
    Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development.
    Fania L; Morelli M; Scarponi C; Mercurio L; Scopelliti F; Cattani C; Scaglione GL; Tonanzi T; Pilla MA; Pagnanelli G; Mazzanti C; Girolomoni G; Cavani A; Madonna S; Albanesi C
    J Pathol Clin Res; 2020 Jan; 6(1):55-68. PubMed ID: 31577850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.